CCM
Cutter Capital Management Portfolio holdings
AUM
$230M
This Quarter Return
+1.95%
1 Year Return
+11.51%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$328M
AUM Growth
+$328M
(+27%)
Cap. Flow
+$61.8M
Cap. Flow
% of AUM
18.82%
Top 10 Holdings %
Top 10 Hldgs %
55.88%
Holding
38
New
12
Increased
9
Reduced
5
Closed
11
Top Buys
| 1 |
Merck
MRK
|
$21.7M |
| 2 |
Amgen
AMGN
|
$20.1M |
| 3 |
Kenvue
KVUE
|
$17.5M |
| 4 |
Ultragenyx Pharmaceutical
RARE
|
$15M |
| 5 |
Cytokinetics
CYTK
|
$12.8M |
Top Sells
| 1 |
Bristol-Myers Squibb
BMY
|
$24.2M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$15.7M |
| 3 |
Acadia Pharmaceuticals
ACAD
|
$12.2M |
| 4 |
Halozyme
HALO
|
$10.4M |
| 5 |
Exelixis
EXEL
|
$9.46M |
Sector Composition
| 1 | Healthcare | 94.68% |
| 2 | Consumer Staples | 5.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Perrigo
PRGO
$3.26B
| $2.57M | 0.78% |
100,000
-222,114
| -69% | -$5.7M |
|
|
27
Acadia Pharmaceuticals
ACAD
$4.45B
| – | – |
-658,409
| Closed | -$12.2M |
|
28
Agios Pharmaceuticals
AGIO
$2.23B
| – | – |
-288,580
| Closed | -$8.44M |
|
|
29
Bristol-Myers Squibb
BMY
$96.1B
| – | – |
-446,900
| Closed | -$24.2M |
|
30
Cabaletta Bio
CABA
$134M
| – | – |
-157,964
| Closed | -$2.69M |
|
|
31
Exelixis
EXEL
$10.1B
| – | – |
-398,762
| Closed | -$9.46M |
|
|
32
Halozyme
HALO
$8.7B
| – | – |
-255,049
| Closed | -$10.4M |
|
33
Ironwood Pharmaceuticals
IRWD
$214M
| – | – |
0
| – | – |
|
34
Eli Lilly
LLY
$653B
| – | – |
-11,040
| Closed | -$8.59M |
|
35
Pliant Therapeutics
PLRX
$98.8M
| – | – |
-194,119
| Closed | -$2.89M |
|
|
36
Regeneron Pharmaceuticals
REGN
$61.1B
| – | – |
-16,360
| Closed | -$15.7M |
|
37
Viridian Therapeutics
VRDN
$1.56B
| – | – |
-278,638
| Closed | -$4.88M |
|
38
Kyverna Therapeutics
KYTX
$160M
| – | – |
-166,514
| Closed | -$4.14M |
|